Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKrittapoom Akrawinthawongen_US
dc.contributor.authorNithima Chaowaliten_US
dc.contributor.authorThanasaporn Chatuparisuthen_US
dc.contributor.authorNoppadol Siritanaratkulen_US
dc.contributor.otherMahidol Universityen_US
dc.identifier.citationHematology. Vol.16, No.2 (2011), 113-122en_US
dc.description.abstractBeta-thalassemia/HbE (beta-thal/HbE) is a thalassemia intermedia (TI) which encompasses a broad spectrum of severity. Here, we used deferiprone (DFP) as an iron chelating agent in TI patients receiving intermittent blood transfusion who are asymptomatic for cardiovascular disease in order to evaluate the effectiveness in iron overload and reduce the possibility of cardiovascular complications. Thirty transfusionin-dependent beta-thal/HbE patients with iron overload were treated with DFP for 1 year. Hematological, biochemical, oxidative stress and echocardiographic parameters were determined. Serum ferritin, nontransferrin-bound iron, and malondialdehyde decreased significantly (P < 0.05) after 1-year treatment with DFP. For echocardiographic results, mean pulmonary arterial pressure and pulmonary vascular resistance were diminished significantly (P < 0.05). All those parameters were still improved after subgroup analysis was done for the high ferritin group ( > 2500 ng/ml). DFP therapy alone improved iron overload and oxidative stress and compliance was good. We propose that prevention of pulmonary hypertension is also possible for TI undergoing intermittent blood transfusion. © W. S. Maney & Son Ltd 2011.en_US
dc.rightsMahidol Universityen_US
dc.titleEffectiveness of deferiprone in transfusionindependent beta-thalassemia/HbE patientsen_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.